The Journal of Practical Medicine >
Quantitative susceptibility mapping analysis of brain iron deposition characteristics and their correlation with cognitive function in Alzheimer's disease patients
Received date: 2025-06-19
Online published: 2025-11-05
Objective To investigate the correlation between brain iron content and cognitive function in patients with Alzheimer's disease (AD), and to assess the diagnostic value of iron deposition in AD using quantitative susceptibility mapping (QSM) technology. Methods Forty-three patients with AD who visited the Second Affiliated Hospital of Xinjiang Medical University between January 2024 and December 2024, and 42 healthy controls matched for gender and age were enrolled in the study. Comprehensive clinical data were collected from all participants. All subjects underwent brain MRI scans using a Philips Ingenia CX 3.0T magnetic resonance imaging system, including both QSM and conventional cranial MRI sequences. The acquired QSM images were post-processed and normalized using the STISuite software package, and the iron content in predefined regions of interest was quantified using ITK-SNAP. All participants also underwent neuropsychological assessments. Differences in regional brain iron content between AD patients and healthy controls were analyzed and compared. Spearman’s correlation coefficient was calculated to evaluate the relationship between iron levels in the frontal cortex, basal ganglia, and hippocampus and cognitive performance. Receiver operating characteristic (ROC) curves were constructed to assess the diagnostic accuracy of iron deposition in differentiating AD patients from healthy controls. Results (1) Compared with the control group, the magnetic susceptibility values in the basal ganglia and hippocampus of the AD group showed statistically significant differences (P < 0.01), with higher values observed in the AD group. No statistically significant difference was found in the susceptibility values of the frontal cortex between the AD group and the control group (P > 0.05). (2) In the AD group, the susceptibility values of the left caudate nucleus and left hippocampus tail were negatively correlated with the MMSE scores (P < 0.05). Additionally, the susceptibility values of the left caudate nucleus, left putamen, left hippocampus, and left hippocampus tail were negatively correlated with the MOCA scores (P < 0.05). (3) The area under the curve (AUC) for diagnosing AD based on the left caudate nucleus was 0.758 (95%CI: 0.649–0.867), for the left putamen it was 0.719 (95%CI: 0.606–0.831), and for the left hippocampus tail it was 0.640 (95%CI: 0.518–0.763). Conclusions (1) The iron content in certain brain regions of AD patients is elevated compared to that in healthy controls, particularly in the basal ganglia and hippocampus. (2) The iron concentration in the brains of AD patients, especially in the left caudate nucleus, left putamen, left hippocampus, and hippocampal tail, is negatively correlated with cognitive function. Higher iron levels are associated with more severe cognitive impairment, suggesting that iron accumulation may serve as a potential biomarker for assessing disease severity. (3) Iron deposition in the left caudate nucleus and left putamen demonstrates certain diagnostic value for AD and holds promise as an imaging marker for the auxiliary diagnosis of the disease.
Yuying SONG , Saimaiti KHALIBINUR , Xu ZHOU , Xiangxin SONG , Yidai Abdigiti XIE , Aizezi DILRABA , Yibulayin. HASYATI . Quantitative susceptibility mapping analysis of brain iron deposition characteristics and their correlation with cognitive function in Alzheimer's disease patients[J]. The Journal of Practical Medicine, 2025 , 41(20) : 3267 -3275 . DOI: 10.3969/j.issn.1006-5725.2025.20.017
| [1] | SCHELTENS P, DE STROOPER B, KIVIPELTO M, et al. Alzheimer's disease[J]. Lancet, 2021, 397(10284): 1577-1590. doi:10.1016/s0140-6736(20)32205-4 |
| [2] | SPOTORNO N, ACOSTA-CABRONERO J, STOMRUD E, et al. Relationship between cortical iron and tau aggregation in Alzheimer's disease[J]. Brain, 2020, 143(5): 1341-1349. doi:10.1093/brain/awaa089 |
| [3] | 郁金泰. 阿尔茨海默病精准诊疗现状和展望[J]. 中华医学信息导报, 2024, 39(17): 16. |
| [4] | 周显波, 裴中. 阿尔茨海默病早发现和早诊断与药物研发现状[J]. 阿尔茨海默病及相关病, 2024, 7(4): 243-246. |
| [5] | PORSTEINSSON A P, ISAACSON R S, KNOX S, et al. Diagnosis of Early Alzheimer's Disease: Clinical Practice in 2021[J]. J Prev Alzheimers Dis, 2021, 8(3): 371-386. doi:10.14283/jpad.2021.23 |
| [6] | FENG L, SUN J, XIA L, et al. Ferroptosis mechanism and Alzheimer's disease[J]. Neural Regen Res, 2024, 19(8): 1741-1750. doi:10.4103/1673-5374.389362 |
| [7] | 张其华, 谭艳. 磁共振定量磁敏感图在中枢神经系统的研究进展[J]. 磁共振成像, 2022, 13(1): 151-153,170. |
| [8] | 张琴, 侯勇哲, 王琳. 阿尔茨海默病脑铁沉积的QSM定量分析研究进展[J]. 医疗卫生装备, 2022, 43(9): 91-96. |
| [9] | JACK C R Jr, ANDREWS S J, BEACH T G, et al. Revised criteria for the diagnosis and staging of Alzheimer's disease[J]. Nat Med, 2024, 30(8): 2121-2124. doi:10.1038/s41591-024-02988-7 |
| [10] | QUINTAS-NEVES M, ALMEIDA F C, GAUTHREAUX K, et al. Fazekas scale magnetic resonance imaging assessment in Alzheimer's disease and primary age-related tauopathy[J]. Neuroradiology, 2024, 66(12): 2185-2193. doi:10.1007/s00234-024-03464-2 |
| [11] | 王金佩,蒋琦,李桂丽,等.新型冠状病毒肺炎对阿尔兹海默症影响的研究进展[J].中国热带医学,2023,23(3):304-309. |
| [12] | MIELKE M M, EVANS J K, NEIBERG R H, et al. Alzheimer Disease Blood Biomarkers and Cognition Among Individuals with Diabetes and Overweight or Obesity[J]. JAMA Netw Open, 2025, 8(2): e2458149. doi:10.1001/jamanetworkopen.2024.58149 |
| [13] | LU Q, SHAO N, FANG Z, et al. The anti-Alzheimer's disease effects of ganoderic acid A by inhibiting ferroptosis-lipid peroxidation via activation of the NRF2/SLC7A11/GPX4 signaling pathway[J]. Chem Biol Interact, 2025, 412: 111459. doi:10.1016/j.cbi.2025.111459 |
| [14] | THORWALD M A, GODOY-LUGO J A, KERSTIENS E, et al. Down syndrome with Alzheimer's disease brains have increased iron and associated lipid peroxidation consistent with ferroptosis[J]. Alzheimers Dement, 2025, 21(6): e70322. doi:10.1002/alz.70322 |
| [15] | THORWALD M A, GODOY-LUGO J A, GARCIA G, et al. Iron-associated lipid peroxidation in Alzheimer's disease is increased in lipid rafts with decreased ferroptosis suppressors, tested by chelation in mice[J]. Alzheimers Dement, 2025, 21(1): e14541. doi:10.1002/alz.14541 |
| [16] | 程峰, 张庸, 王祥, 等. 谷胱甘肽过氧化物酶GPX4在铁死亡中的作用与机制研究进展[J]. 现代肿瘤医学, 2021, 29(7): 1254-1258. |
| [17] | BUTTERFIELD D A. Brain lipid peroxidation and Alzheimer disease: Synergy between the Butterfield and Mattson laboratories[J]. Ageing Res Rev, 2020, 64: 101049. doi:10.1016/j.arr.2020.101049 |
| [18] | BUTTERFIELD D A, BOYD-KIMBALL D. Mitochondrial Oxidative and Nitrosative Stress and Alzheimer Disease[J]. Antioxidants (Basel), 2020, 9(9): 818. doi:10.3390/antiox9090818 |
| [19] | 张金彪, 张凤翔, 高嘉璐. 定量磁化率成像技术在认知功能障碍中的研究进展[J]. 磁共振成像, 2023, 14(9): 114-118,130. |
| [20] | ZHU W Z, ZHONG W D, WANG W, et al. Quantitative MR phase-corrected imaging to investigate increased brain iron deposition of patients with Alzheimer disease[J]. Radiology, 2009, 253(2): 497-504. doi:10.1148/radiol.2532082324 |
| [21] | LIU X, DU L, ZHANG B, et al. Alterations and associations between magnetic susceptibility of the basal ganglia and diffusion properties in Alzheimer's disease[J]. Front Neurosci, 2021, 15: 616163. doi:10.3389/fnins.2021.616163 |
| [22] | GHADERI S, MOHAMMADI S, NEZHAD N J, et al. Iron quantification in basal ganglia: Quantitative susceptibility mapping as a potential biomarker for Alzheimer's disease - a systematic review and meta-analysis[J]. Front Neurosci, 2024, 18: 1338891. doi:10.3389/fnins.2024.1338891 |
| [23] | QIN Y, ZHU W, ZHAN C, et al. Investigation on positive correlation of increased brain iron deposition with cognitive impairment in Alzheimer disease by using quantitative MR R2' mapping[J]. J Huazhong Univ Sci Technolog Med Sci, 2011, 31(4): 578. doi:10.1007/s11596-011-0493-1 |
| [24] | CHEN W, JIANG L F, HU Y Q, et al. Ferritin reduction is essential for cerebral ischemia-induced hippocampal neuronal death through p53/SLC7A11-mediated ferroptosis[J]. Brain Res, 2021, 1752: 147216. doi:10.1016/j.brainres.2020.147216 |
| [25] | BAO W D, PANG P, ZHOU X T, et al. Loss of ferroportin induces memory impairment by promoting ferroptosis in Alzheimer's disease[J]. Cell Death Differ, 2024, 31(8): 1099. doi:10.1038/s41418-024-01290-w |
| [26] | SCHWIMMBECK F, BULLóN TARRASó E, SCHREINER T. A role for respiration in coordinating sleep oscillations and memory consolidation[J]. Trends Neurosci, 2025, 48(4): 247-249. doi:10.1016/j.tins.2025.02.005 |
| [27] | WANG D, LI Y Y, LUO J H, et al. Age-related iron deposition in the basal ganglia of controls and Alzheimer disease patients quantified using susceptibility weighted imaging[J]. Arch Gerontol Geriatr, 2014, 59(2): 439-449. doi:10.1016/j.archger.2014.04.002 |
| [28] | 金泉伟, 杨小梅. 增加铁沉积对脑定量敏感性的映射与阿尔茨海默病中认知功能降低之间关系的研究[J]. 脑与神经疾病杂志, 2019, 27(10): 625-630. |
| [29] | 申杰, 徐桂华. 阿尔茨海默病与血脑屏障的相关性研究进展[J]. 实用医学杂志, 2024, 40(11): 1602-1606. |
| [30] | LI R, FAN Y R, WANG Y Z, et al. Brain iron in signature regions relating to cognitive aging in older adults: The Taizhou Imaging Study[J]. Alzheimers Res Ther, 2024, 16(1): 211. doi:10.1186/s13195-024-01575-9 |
| [31] | DU L, ZHAO Z, CUI A, et al. Increased iron deposition on brain quantitative susceptibility mapping correlates with decreased cognitive function in Alzheimer's disease[J]. ACS Chem Neurosci, 2018, 9(7): 1849-1857. doi:10.1021/acschemneuro.8b00194 |
| [32] | 黎超洋, 崔凯茵, 房国梁. 铁代谢在运动改善阿尔茨海默病中的作用与机制研究进展[J]. 中国体育科技, 2023, 59(6): 46-55. |
/
| 〈 |
|
〉 |